From 76ed5e78ca3833ee5be6446584ed557c3d47d452 Mon Sep 17 00:00:00 2001 From: Ruben Date: Tue, 21 Oct 2025 21:15:27 +0200 Subject: [PATCH] Update frontpage and contact information Update contact details and social media links Add "Learn more" button to front page Remove English frontpage and contact page Improve call-to-action section text --- content/frontpage.en.php | 79 ------------------------------------ content/frontpage.php | 3 +- content/kontakt/page.en.html | 6 --- content/kontakt/page.html | 2 +- custom/templates/base.php | 2 +- 5 files changed, 4 insertions(+), 88 deletions(-) delete mode 100644 content/frontpage.en.php delete mode 100644 content/kontakt/page.en.html diff --git a/content/frontpage.en.php b/content/frontpage.en.php deleted file mode 100644 index f1a6ca6..0000000 --- a/content/frontpage.en.php +++ /dev/null @@ -1,79 +0,0 @@ -
-
-

The patients who fall through the cracks

-
-
- -
-

Who are we?

-

We are an advocacy organization working to ensure that patients who could benefit from medical cannabis receive equal and safe treatment with medical follow-up. The medication group should be financially accessible through public reimbursement schemes, and patients should not lose fundamental rights when receiving legal medicine!

- -

What do we want to achieve?

-

Our goal is to find a solution to the challenging situation faced by Norwegian patients, doctors, and researchers regarding the use of medical cannabis (MC) in treatment. We aim to do this by establishing a registry study in Norway, along with the following implementation criteria that must be met for the study to be realized:

- -

1. Registry study in international collaboration

-

We are working to ensure that Norway implements Europe's largest registry study on medical cannabis, developed at Imperial College London. The study follows up on all users of medical cannabis—regardless of their condition or the type of cannabis they use. This way, we can gain an overview of which variants of the medication group work best for different conditions, along with any side effects that may occur. We are already in dialogue with several Norwegian researchers who want to contribute to this effort.

- -

2. Broad indication for assessment

-

For the study to provide us with expanded knowledge, we need to change the current situation where it is nearly impossible for patients to obtain a prescription for medical cannabis in Norway. This is despite the fact that the medication group is already considered low-risk in a medical context. We want it to be recognized that cannabis affects the body's endocannabinoid system, meaning it can help with many different diseases and ailments. We therefore believe that doctors should be able to try medical cannabis for all conditions where the patient has not received adequate help from other medications—as long as there are no medical reasons to avoid it.

- -

3. General prescribing rights for all doctors

-

We want doctors who are already authorized to prescribe strong medications (Class A and B drugs) to also be able to prescribe medical cannabis to their patients. We are working to ensure that the doctor who knows the patient best—and who regularly follows up with them—is also the one who makes the decision about medical cannabis. We believe this will provide better follow-up and more holistic treatment for patients. It will also be an important relief for a specialist healthcare service that is already overworked and has long waiting lists.

- -

4. Coverage of medication expenses

-

A medication is not truly accessible if the patient cannot afford it. Everyone who receives a prescription for medical cannabis should have their costs covered by the public system, just like with other medications. Today, patients mostly have to pay for everything themselves, creating a two-tiered system where only those with good finances have access to treatment. This leads many patients to buy cannabis illegally, where it is cheaper but lacks quality control and safety.

- -

5. Continuing education for doctors and healthcare professionals

-

It is important that the prescription of medical cannabis is done in a safe and responsible manner. There is therefore a need for doctors to be offered courses and training on how medical cannabis is used to treat various diseases. Doctors themselves say they lack knowledge in this area, which is also confirmed by studies. Without sufficient knowledge, doctors cannot provide patients with the best treatment or feel confident in prescribing medical cannabis.

- -

6. Review of health requirements for driver's licenses

-

For patients to be able to participate in the study, there is a need for a thorough review of the regulations regarding driver's licenses and medical cannabis. As the only country in Europe, Norway has regulations that result in most patients losing their driving privileges when prescribed medical cannabis—even if they use variants and doses that do not impair their ability to drive. For other medications that may temporarily affect driving ability, Norway operates on a trust-based system. The current regulations therefore discriminate against patients using medical cannabis.

- -

What is medical cannabis?

-

Medical cannabis is not a single medicine but a group of medications. The medications come in various forms of administration such as capsules, oils, tablets, plant material, and oral sprays. There are three categories of medical products prescribed:

- - - -

Each product in these categories has a unique combination of active ingredients and form of administration. A patient who does not respond to one variant of the medication, such as Sativex, may still benefit from another variant and/or form of administration. In Norway, we currently have 19 variants of medical cannabis (MC). In comparison, England has 240 variants.

- -

The most well-known active ingredients in MC are THC and CBD. THC can increase appetite and reduce nausea. It can also relieve pain, inflammation, and muscle control problems. In cases of overdose, THC can produce a euphoric effect (intoxication). CBD is not intoxicating but can have a relaxing effect. CBD can reduce pain and inflammation, control epileptic seizures, and may potentially help in the treatment of mental illness and addiction. In addition, we find smaller amounts of other cannabinoids such as CBG, CBN, and THCV, as well as non-cannabinoid phenols, flavonoids, terpenes, and alkaloids. These work together in an "entourage" effect and contribute to each variant of the medication having unique effects. This also means that MC should be tailored individually to each patient's needs.

- -

The active ingredients in cannabis act on a large receptor system in the body called the endocannabinoid system. This consists of three main components: endocannabinoids (such as anandamide and 2-AG), CB1 and CB2 receptors, and regulatory enzymes. The endocannabinoid system's main task is to maintain the body's natural balance, or homeostasis. It is central in regulating many important processes such as anxiety, pain, inflammation, stress and immune responses, mood, and appetite. Dysregulations in the system are also believed to influence the development of symptoms in Huntington's disease, Alzheimer's disease, Parkinson's disease, and multiple sclerosis (MS). The effect on the endocannabinoid system explains why cannabis can have an effect on so many symptoms and diagnoses. Approximately 50% of prescriptions currently written in England are for all types of chronic pain, 40% for various mental health conditions, 6% for neurological conditions, and 4% for other diagnoses.

- -

Cannabis is associated with several misunderstandings and stigmas due to the fact that the active ingredient THC can also be used as a recreational drug. Variants containing less than 1% THC cannot produce an intoxicating effect. This typically applies to isolated CBD (such as in Epidyolex) or whole-plant CBD with GMP standard. For higher amounts of THC, the following applies: In medical use, intoxication is considered an unwanted side effect that can occur with THC overdose. In this regard, medical cannabis is not unique—many medications can cause intoxication when overdosed. It all depends on dosage, titration, adaptation, and the content of active ingredients. Common doses of THC for medical use typically range between 0.5–20 mg per day after adaptation, comparable to medications like Lyrica and benzodiazepines. Starting doses are usually between 0.5–2.5 mg of THC per day. For comparison, a single recreational dose is considered to start from 10 mg of THC for inexperienced users, and often exceeds 50 mg per dose for experienced users.

- -

Addiction potential is a concern for many, which is understandable given the experiences with OxyContin and the aggressive marketing associated with it. MC is minimally physically addictive. An RCT study examining what happens with rapid discontinuation of Sativex found no withdrawal problems after 3 years of use. Another RCT study following arthritis patients over 5 months showed no issues related to stopping treatment. In recreational use, it is estimated that around 9% develop addiction, but the concept of addiction should be used with caution when discussing medical use, as discontinuation often results in the return of symptoms that MC is used to treat. Tolerance development (requiring increased doses) may occur, but this is managed by the doctor monitoring dose development and implementing tapering periods if necessary.

-
- - diff --git a/content/frontpage.php b/content/frontpage.php index fc8f2a5..dbdfff8 100644 --- a/content/frontpage.php +++ b/content/frontpage.php @@ -6,7 +6,7 @@
-

Vi ber om hjelp til å åpne dører. Vi har laget enkle brosjyrer som kan deles med pasienter, fagpersoner, pasientforeninger og politikere. Last ned, skriv ut og del!

+

Hjelp oss å åpne dører! Vi har laget enkle brosjyrer som kan deles med pasienter, fagpersoner, pasientforeninger og politikere.

Last ned, skriv ut og del!

Vis brosjyrer
@@ -14,6 +14,7 @@

Hvem er vi?

Vi er en frivillig interesseorganisasjon som arbeider for at pasienter som kan ha nytte av medisinsk cannabis skal motta likeverdig og trygg behandling med oppfølging fra lege. Medikamentgruppen skal være økonomisk tilgjengelig gjennom offentlig refusjonsordninger og pasienter skal ikke miste grunnleggende rettigheter når de mottar lovlig medisin!

+ Les mer om oss

Hva ønsker vi å oppnå?

Målet er å finne en løsning på den utfordrende situasjonen som norske pasienter, leger og forskere står overfor når det gjelder bruk av medisinsk cannabis (MC) i behandling. Dette søker vi å gjøre ved å opprette en registerstudie og prøveordning i Norge, sammen med flere gjennomføringskriterier som må være oppfylt for at studien skal kunne realiseres:

diff --git a/content/kontakt/page.en.html b/content/kontakt/page.en.html deleted file mode 100644 index 818fdd6..0000000 --- a/content/kontakt/page.en.html +++ /dev/null @@ -1,6 +0,0 @@ -
-

Contact Us

-

Write to us at kontakt@stopplidelsen.no

-

About Us

-

The advocacy organization "Stopp lidelsen" (Stop the Suffering) was established in the winter of 2024/25 with the goal of finding a solution to the challenging situation faced by Norwegian patients, doctors, and researchers regarding the use of medical cannabis (MC) in treatment. We have all worked on this issue for several years and consist of experienced representatives from multiple patient associations, in close dialogue with experts both domestically and internationally. In recent years, we have also united several patient associations behind this initiative.

-
diff --git a/content/kontakt/page.html b/content/kontakt/page.html index dac244c..dede9f8 100644 --- a/content/kontakt/page.html +++ b/content/kontakt/page.html @@ -1,6 +1,6 @@

Kontakt oss

-

Skriv til oss på kontakt@stopplidelsen.no

+

Skriv til oss på kontakt æt stopplidelsen dåt no og følg oss på Facebook, Instagram og Mastodon.

Kort om oss

Interesseorganisasjonen Stopp lidelsen ble opprettet vinteren 2024/25 med mål om å finne en løsning på den utfordrende situasjonen for norske pasienter, leger og forskere når det gjelder bruk av medisinsk cannabis (MC) i behandling i Norge.

Vi har alle jobbet med saken over flere år og består av fagpersoner, pårørende og erfarne representanter fra flere pasientforeninger. Vi har knyttet til oss leger, helsepersonale og forskere i både inn- og utland som vi samarbeider tett med.

diff --git a/custom/templates/base.php b/custom/templates/base.php index 24515e5..c14fcce 100644 --- a/custom/templates/base.php +++ b/custom/templates/base.php @@ -52,7 +52,7 @@ function getActiveClass($href) { return rtrim(parse_url($_SERVER['REQUEST_URI'],